Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Stopped early · Phase 2

Conditions studied: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Stage 3 Cancer, Stage 4 Cancer

In brief

The primary objective is to determine whether the addition of bevacizumab to a regimen of carboplatin plus paclitaxel significantly improves Progression Free Survival (PFS) for patient with Stage III suboptimally cytoreduced or Stage IV ovarian, primary peritoneal or fallopian tube carcinomas.

Key facts

Study ID

NCT00408070

Run by

UConn Health

People needed

5

Starts

2006-10-01

Expected to finish

2009-10-01

Last updated by the study team

2018-03-08

Who can join

Age: 19 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• diagnosis of primary peritoneal carcinoma, fallopian tube epithelial ovarian carcinoma,
• stage III suboptimal surgery or biopsy,
• stage IV disease
• no prior chemotherapy

You may not qualify if…

• unstable heart conditions
• high blood pressure
• vascular disorders
• bleeding problems

Where it is running

• University of Connecticut Health Center — Farmington, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.